You are here

Article Text

Article menu

Download PDFPDF

Epidemiology & Outcomes
610 Predictors of first hospitalizations due to disease activity and infections in systemic lupus erythematosus patients
  1. Rosana Quintana1,
  2. Romina Nieto1,
  3. Rosa Serrano Morales1,
  4. Manuel F Ugarte-Gil2,
  5. Guillermina B Harvey3,
  6. Daniel Wojdyla3,
  7. Jose A Gómez-Puerta4,
  8. Mercedes García5,
  9. Luis Catoggio6,
  10. Veronica Saurit7,
  11. Cristina Drenkard8,
  12. Nílzio Da Silva9,
  13. Fernando Cavalcanti10,
  14. Eduardo Borba11,
  15. Emília Sato12,
  16. Oscar Neira13,
  17. Loreto Massardo14,
  18. Gloria Vásquez15,
  19. Luis Alonso González16,
  20. Marlene Guibert-Toledano17,
  21. Luis Humberto Silveira Torre18,
  22. Ignacio Garcia-De La Torre19,
  23. Maria Josefina Sauza DEL Pozo20,
  24. Rosa Chacon21,
  25. Graciela S Alarcon22,
  26. Ashley Orillion23,
  27. Urbano Sbarigia24,
  28. Federico Zazzetti25,
  29. Bernardo Pons-Estel1 and
  30. Guillermo Pons-Estel1
  1. 1Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rheumatology, ROSARIO, Argentina
  2. 22Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Rheumatology, Lima, Peru
  3. 3Facultad de Ciencias Económicas y Estadística. Universidad Nacional de Rosario, Escuela de Estdística, ROSARIO, Argentina
  4. 4Hospital Clinic, Rheumatology, Barcelona, Spain
  5. 5HIGA San Martin de La Plata, Rheumatology, La Plata, Argentina
  6. 6Hospital Italiano de Buenos Aires, Rheumatology Section, Buenos Aires, Argentina
  7. 7Hospital Privado Universitario de Córdoba, Rheumatology, Cordoba, Argentina
  8. 8Emory School of Medicine, Division of Rheumatology, Department of Medicine, Atlanta, USA
  9. 9Hospital das Clínicas, Universidade Federal de Goiás, Reumatologia/Departamento de Clínica Médica, Goias, Brazil
  10. 10Centro de Ciências Médicas, Hospital das Clínicas, Universidade Federal de Pernambuco, Serviço de Reumatologia, Departamento de Medicina Clínica, Pernambuco, Brazil
  11. 11Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Rheumatology Division, São Paulo, Brazil
  12. 12Escola Paulista de Medicina, Universidad Federal São Paulo, Rheumatology, São Paulo, Brazil
  13. 13Hospital del Salvador, Universidad de Chile, Rheumatology Division, Santiago de Chile, Chile
  14. 14Facultad de Medicina y Ciencia, Universidad San Sebastián, Rheumatology Division, San Sebastián, Chile
  15. 15Facultad de Medicina, Universidad de Antioquía, Grupo de Inmunología Celular e Inmunogenética, Medellín, Colombia
  16. 16Universidad de Antioquía, Sección de Reumatología, Departamento de Medicina Interna, Medellin, Colombia
  17. 17Centro de Investigaciones Médicas Quirúrgicas, Rheumatology Division, Havana, Cuba
  18. 18Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología/Departamento de Reumatología, Mexico, Mexico
  19. 19Hospital General de Occidente de la S.S. Universidad de Guadalajara, Departamento de Inmunología y Reumatología, México, Mexico
  20. 20Instituto Mexicano de Seguro Social, Hospital de Especialidades N° 25, Rheumatologymex, Monterrey, Mexico
  21. 21Policlínica Méndez Gimón, Servicio de Reumatología, Caracas, Venezuela (Bolivarian Republic)
  22. 22Max Heersink School of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, USA
  23. 23Janssen Research and Development, Rheumatology, Horsham, USA
  24. 24Janssen Pharmaceutica NV, Rheumatology, Beerse, Belgium
  25. 25Janssen Pharmaceutical Companies of Johnson and Johnson, Rheumatology, Horsham, USA

Abstract

Background Systemic Lupus Erythematosus (SLE) patients experience frequent hospitalizations; lupus flares and infections have been shown to be the two most common causes.

Objectives The aim of this study is to describe the main causes and predictors of first hospitalizations due to disease activity and infections in SLE patients.

Methods SLE patients from GLADEL, a multi-ethnic, multi-national Latin-American (LA) cohort were studied. The first hospitalization during these patients’ follow-up due to either infection and/or SLE disease activity was examined. Baseline sociodemographic, clinical, damage (SDI) and treatments were evaluated as possible predictors. First, descriptive analyses were performed. Predictors of infection or SLE disease activity associated hospitalization were identified using univariate and multivariate logistic.

Results A total of 1341 patients were included; 1201 (89.6%) were female. Their median interquartile range (IQR) age at diagnosis was 27 (20–37) years and their median IQR follow up time 27.5 (4.7–62.2) months. 456 (34.9%) patients were hospitalized; 344 (75.4%), 85 (18.6%) and 27 (5.9%) were hospitalized for disease activity, infections, or both, respectively, as depicted in figure 1. In the multivariable analysis, arthritis was associated with hospitalizations due to infection. Serositis, disease activity and damage were associated with hospitalizations due to disease activity. Older age, higher socioeconomic status and antimalarial use were found to be protective, as depicted in table 1.

Abstract 610 Figure 1
Abstract 610 Figure 1

Reasons for the first hospitalizations

View this table:
Abstract 610 Table 1

Univariable and multivariable logistic regression analysis of predictors of hospitalization due to disease activity and infections in patients with SLE.

Conclusion In this large LA lupus cohort, one third of the patients had at least one hospitalization; of them, were due to SLE disease activity. Our findings call attention for controlling disease activity and preventing damage using antimalarials early in the disease course disease to prevent the first hospitalization.

Lay summary We report hospitalization rates among Latin American patients with systemic lupus erythematosus. One third of Latin American patients were hospitalized at least once, the majority of which were due to disease activity. Antimalarial drugs can help prevent damage in early disease and prevent hospitalization.

Disclosure of interest: Rosana Quintana: None declared, Romina Nieto: None declared, Rosa Serrano Morales: None declared, Manuel F. Ugarte-Gil: None declared, Guillermina B. Harvey: None declared, Daniel Wojdyla: None declared, Jose A. Gómez-Puerta: None declared, Mercedes García: None declared, Luis Catoggio: None declared, Veronica Saurit: None declared, Cristina Drenkard: None declared, Nílzio da Silva: None declared, Fernando Cavalcanti: None declared, Eduardo Borba: None declared, Emília Sato: None declared, Oscar Neira: None declared, loreto massardo: None declared, Gloria Vásquez: None declared, Luis Alonso González: None declared, Marlene Guibert- Toledano: None declared, Luis Humberto Silveira Torre: None declared, Ignacio Garcia-De La Torre: None declared, MARIA JOSEFINA SAUZA DEL POZO: None declared, Rosa Chacon: None declared, Graciela S Alarcon: None declared, Ashley Orillion Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, USA, Urbano Sbarigia Employee of: Janssen Pharmaceutica NV, Beerse, BE, Federico Zazzetti Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA, Bernardo Pons-Estel: None declared, Guillermo Pons- Estel: None declared.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/lupus-2023-lupus21century.41

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.